

## FEDAC

### PRODUCT DESCRIPTION:

Tablets : Light pink, round and flat tablets, 8 mm diameter with score line and "DHA" logo.

Syrup : Clear mixture, yellow in colour, sweet taste with orange flavour.

### COMPOSITION:

- |              |                        |               |
|--------------|------------------------|---------------|
| 1) Tablets : | Triprolidine HCl BP    | 2.5 mg/tablet |
|              | Pseudoephedrine HCl BP | 60 mg/tablet  |
| 2) Syrup :   | Triprolidine HCl BP    | 1.25 mg/5 ml  |
|              | Pseudoephedrine HCl BP | 30 mg/5 ml    |

### PRESERVATIVES:

Methyl hydroxybenzoate 0.15% w/v

Propyl hydroxybenzoate 0.015% w/v

### PHARMACOLOGY:

Triprolidine is an antihistamine which competes with histamine for H-receptor sites on effector cells. It prevents but does not reverse responses mediated by histamine alone. Its anti-cholinergic actions provide a drying effect on the nasal mucosa. Pseudoephedrine acts on alpha-adrenergic receptors in the mucosa of the respiratory tract, producing vasoconstriction. It shrinks swollen nasal mucous membrane, reduces tissue hyperemia, oedema and nasal congestion, and increases nasal airway patency. Also drainage of sinus secretions may be increased and obstructed eustachian ostia may be opened.

### INDICATIONS:

Symptomatic treatment of nasal and respiratory congestion, common cold, acute sinusitis, allergic rhinitis.

### RECOMMENDED DOSAGE:

Tablet : Adult : 1 tablet 3 times a day

Syrup : Adults and children over 12 years : 2 teaspoonfuls 3 times a day.

Children : 6 - 12 years : 1 teaspoonful,

2 - 5 years : ½ teaspoonful.

Doses to be taken 3 times a day.

Note : 1 teaspoonful is equal to 5ml.

### CAUTION:

Not to be used in children less than 2 years of age.

To be used with caution and on doctor's or pharmacist's advice in children 2 to 6 years of age.

### ADVERSE EFFECTS:

Drowsiness, dryness of mouth, nervousness, restlessness, trouble in sleeping.

### PRECAUTIONS:

Patients sensitive to one antihistamine or sympathomimetic may be sensitive to others. Triprolidine may cause drowsiness. If affected do not drive or operate machinery.

PHARMACODE  
AREA

## AAAM7163- Triprolidine HCl/Pseudoephedrine HCl, Fedac 1.25/30 mg -, PIL, Singapore

### GENERAL INFORMATION

Proof Round: 2  
Origination Date: 18.11.2020  
Originated by: GT  
Revision Date: 01.12.2020  
Revised by: GT

Dimensions: 120x208 mm  
Manuf. site: Actavis Jakarta  
Min pt size\*: 10 pt  
SAP Code:

### TECHNICAL CHECK

Date Sent: 27.11.2020  
Resent Date:  
Approval Date: 30.11.2020

### NON- PRINTING COLOURS

1. Profile ●  
2.  
3.

### COLOURS/PLATES

1. Black ●  
2.  
3.  
4.  
5.  
6.

teva

awstudio@tevapharm.com

\*Note that smaller packaging dimensions may result in lower point size than your required font size.

**Supplier Instructions** Artwork, text and content must NOT be altered. The only exceptions to this are: bleeds, chokes, spreads or other adjustments required for print reproduction purposes only. If you have any difficulties please contact the Teva Artwork Team. We must receive a copy of the 3rd Party Vendros Proof before final approval can be made.

**USE IN PREGNANCY:**

There are no specific data on the use of triprolidine and pseudoephedrine during pregnancy. Caution should therefore be exercised by weighing the potential benefits against the possible risks to the foetus before prescribing the drug.

**CONTRAINDICATIONS:**

Individuals who are hypersensitive to any component in this product, patients with severe hypertension or severe coronary artery disease; patients who are taking or have taken MAOis within the preceding 2 weeks; patients with hyperthyroidism.

**DRUG INTERACTIONS:**

Concomitant use of Fedac with sympathomimetic agents or with MAOis may cause a rise in blood pressure.  
Pseudoephedrine may reverse the hypotensive activity of drugs which interfere with sympathetic activity.  
Triprolidine may enhance the drowsiness caused by sedative drugs and alcohol.

**SYMPTOMS AND TREATMENT OF OVERDOSAGE:**

Symptoms : Restlessness, delirium and muscle tremors.  
Treatment: Give activated charcoal and then remove the drug by airway protected gastric lavage followed by catharsis.

**AVAILABILITY:**

Tablets : 10 x 10 x 10's blister pack  
Syrup : 3.8 litres in high density polyethylene container with cap.  
120 ml in amber glass bottle.

**EXPIRY PERIOD AND STORAGE:**

Do not use after the expiry date stated on the label. Store below 30°C and protect from light.

**DATE OF REVISION : November 2020**

For further information, please consult your physician or pharmacist

Manufactured by:  
PT Actavis Indonesia  
JL. Raya Bogor KM 28  
Jakarta  
Indonesia, 13710

**teva**  
AAAM7163

PHARMACODE  
AREA

## AAAM7163- Triprolidine HCl/Pseudoephedrine HCl, Fedac 1.25/30 mg -, PIL, Singapore

### GENERAL INFORMATION

**Proof Round:** 2  
**Origination Date:** 18.11.2020  
**Originated by:** GT  
Revision Date: 01.12.2020  
Revised by: GT

**Dimensions:** 120x208 mm  
**Manuf. site:** Actavis Jakarta  
**Min pt size\*:** 10 pt  
**SAP Code:**

### TECHNICAL CHECK

**Date Sent:** 27.11.2020  
**Resent Date:**  
**Approval Date:** 30.11.2020

### NON- PRINTING COLOURS

1. Profile ●  
2.  
3.

### COLOURS/PLATES

1. Black ●  
2.  
3.  
4.  
5.  
6.

**teva**

awstudio@tevapharm.com

\*Note that smaller packaging dimensions may result in lower point size than your required font size.

**Supplier Instructions** Artwork, text and content must NOT be altered. The only exceptions to this are: bleeds, chokes, spreads or other adjustments required for print reproduction purposes only. If you have any difficulties please contact the Teva Artwork Team. We must receive a copy of the 3rd Party Vendros Proof before final approval can be made.